In a nationwide Korean cohort of men aged 65 and older, metabolic dysfunction-associated steatotic liver disease (MASLD) carried an 11% higher bladder cancer risk (adjusted HR 1.11, 95% CI 1.01-1.21) after inverse probability weighting and accounting for death as a competing event. Incidence was 1.17% versus 1.11% in non-SLD men. The signal persisted in never smokers after excluding cases diagnosed within three years. Men with MetALD showed an apparent 33% lower risk (aHR 0.67), and associations were stronger under age 75.
The MASLD finding fits a growing pattern linking fatty liver to extrahepatic cancers, plausibly through insulin resistance, chronic low-grade inflammation, and altered hormone signaling. But an 11% relative increase, with a lower confidence bound barely above 1.0, is small, and the absolute difference was about 0.06 percentage points. Treat this as hypothesis-supporting rather than actionable on its own. The MetALD result deserves skepticism: a protective effect of added alcohol is biologically implausible and more likely reflects residual confounding, such as smoking intensity, self-reported drinking, or healthy-drinker effects. The authors' survivor bias handling helps, but a single baseline exposure measurement in 2009-2010 and diagnosis codes for steatosis limit precision. Findings in elderly Korean men may not generalize to women or other ancestries. Practically, the study reinforces that managing metabolic health, weight, glucose control, and avoiding smoking, the dominant bladder cancer risk factor, matters well beyond the liver. Overall, this is an incremental, confirmatory observational result, not a reason for bladder cancer screening in people with fatty liver.